Next Article in Journal
The Interplay of LncRNA-H19 and Its Binding Partners in Physiological Process and Gastric Carcinogenesis
Next Article in Special Issue
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Previous Article in Journal
Exhaled Breath Metabolomics for the Diagnosis of Pneumonia in Intubated and Mechanically-Ventilated Intensive Care Unit (ICU)-Patients
Previous Article in Special Issue
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(2), 448; doi:10.3390/ijms18020448

Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations

1,* and 2,*
1
Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USA
2
Burt Consultancy, 2616 Erwin Rd, Durham, NC 27705, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Sabrina Angelini and Gloria Ravegnini
Received: 16 December 2016 / Revised: 17 January 2017 / Accepted: 18 January 2017 / Published: 19 February 2017
(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine 2016)
View Full-Text   |   Download PDF [4326 KB, uploaded 19 February 2017]   |  

Abstract

Pharmacoproteomics is the study of disease-modifying and toxicity parameters associated with therapeutic drug administration, using analysis of quantitative and temporal changes to specific, predetermined, and select proteins, or to the proteome as a whole. Pharmacoproteomics is a rapidly evolving field, with progress in analytic technologies enabling processing of complex interactions of large number of unique proteins and effective use in clinical trials. Nevertheless, our analysis of clinicaltrials.gov and PubMed shows that the application of proteomics in early-phase clinical development is minimal and limited to few therapeutic areas, with oncology predominating. We review the history, technologies, current usage, challenges, and potential for future use, and conclude with recommendations for integration of pharmacoproteomic in early-phase drug development. View Full-Text
Keywords: proteome; proteomics; drug development; early phase development; clinical development; biomarker; Omics; clinical research; phase 0; phase 1; phase 2; proof-of-concept; proof-of-mechanism; proof-of-principle; first-in-human (FIH) studies; pharmacogenomics; pharmacometabolomics; pharmacokinetics (PK); pharmacodynamics (PD); drug toxicity proteome; proteomics; drug development; early phase development; clinical development; biomarker; Omics; clinical research; phase 0; phase 1; phase 2; proof-of-concept; proof-of-mechanism; proof-of-principle; first-in-human (FIH) studies; pharmacogenomics; pharmacometabolomics; pharmacokinetics (PK); pharmacodynamics (PD); drug toxicity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nandal, S.; Burt, T. Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. Int. J. Mol. Sci. 2017, 18, 448.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top